Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
September 25, 2023
A promising HIV vaccine candidate gets a little help
New strategy stirs a robust response from T cells tracked by McElrath lab
Year in Pictures: 2022
A look back at the year through compelling images
Could a 100-year-old TB vaccine help scientists find a better one?
Harmless vaccine BCG is made of living bacteria; in tests might serve as a proxy for deadly tuberculosis
Dr. Larry Corey receives Alexander Fleming Award
Virologist honored by peers for his lifetime achievements against infectious diseases
Fauci visits Fred Hutch, discusses pandemics, vaccines and scientific misinformation
NIAID director’s determined spirit recognized with honorary Hutch Award
Test of a new 'germline-targeting' HIV vaccine prepares to launch
Vaccine’s unique protein designed to start process of building powerful antibodies against AIDS virus
IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology
Phase 1 trial aims to build on response seen in proof-of-concept trial
Highlights of Fred Hutch science in 2021
From COVID-19 to cancer, Hutch scientists pursued new ideas to save lives
Increasing BIPOC inclusion in clinical trials
From the COVID-19 Prevention Network, Vaccine and Infectious Disease Division
World AIDS Day 2021: Let's give the gifts of hope and focus to HIV research
HIV scientific infrastructure paved the way for the world’s COVID-19 response. Now, it’s time to return the favor.
Experimental Phase 2b HIV Vaccine Regimen Provides Insufficient Protection in Preventing HIV
No safety signals of concern for study participants
AIDS@40: Stories of hope and heroes
The people and the science devoted to stopping HIV
Community engagement in HIV trials guides equity for COVID-19 vaccine studies
New study highlights longstanding barriers to diversity in prior decade of vaccine trials, despite federal guidelines
HIV vaccine trials are complicated by the availability of PrEP
World AIDS Day 2020: Vaccine researchers still find ways to run trials amid growing use of HIV-prevention drugs
Tailoring vaccine trial recruitment to individual communities
From the HVTN, Vaccine and Infectious Disease Division
Benefits outweigh the social stigma of HIV vaccine trial participation
From the HIV Vaccine Trials Network and the University of Washington
Q&A: Dr. Larry Corey at the center of COVID-19 vaccine research
Fred Hutch scientists will play key roles in 'harmonizing' clinical trials
HIV vaccine trial uncovers plausible mechanisms of protection
From the HVTN, Vaccine and Infectious Disease Division
New HIV vaccine trial to launch in U.S., Latin America and Europe
‘Mosaico’ will enroll 3,800 transgender people and men who have sex with men